Dr Nigel Greenwood
Co-Founder/CEO

Nigel is a mathematician and inventor of the Neuromathix technology and patents: new forms of evolutionary machine learning and adversarial AI, constructed using completely different mathematical approaches than neural networks, hence generating new machine learning and AI capabilities beyond neural networks. Holding first class honours in pure mathematics and a PhD in differential game theory, he is a former Honorary Senior Fellow of the School of Mathematics and Physics at the University of Queensland. A former senior analyst in the Australian Government, he is experienced in running research programmes in both public and private sectors. He is one of Australia’s Spitfire Memorial Defence Fellows.

In 2001, he founded NeuroTech Research Pty Ltd (NTR), which was awarded a Queensland Government Innovation Start-Up Scheme (ISUS) grant for the development of software to aid medication of a number of chronic diseases, leading to the Neuromathix software. The company was a member of the Queensland Government's i.lab Incubator, a technology incubator for promising start-ups.

At that time practical deployment of the Neuromathix algorithms had to be delayed until cheap, scalable massively-parallel computing platforms became available. With the advent of NVIDIA's GPU computing architectures, a suitable computing platform now exists. In the interim, he began laying down a strong IP position in patents.

In other scientific fields, he was awarded the 2004 and 2007 Spitfire Memorial Defence Fellowships by the University of New South Wales for ongoing research in machine intelligence in aerospace. In 2011-2013 he was Honorary Senior Fellow in the School of Mathematics and Physics at the University of Queensland.

Nigel is a director and CEO of Diabetes Neuromathix Pty Ltd (DNx), the spin-off company dedicated to the commercialisation of the Neuromathix artificial pancreas software.

From 2016 to 2020, Nigel was team leader of Team MachineGenes, one of the teams in the IBM Watson AI XPRIZE, showcasing the DNx technology. In January 2020 Team MachineGenes was one of the ten global semifinalists in the AI XPRIZE.

In 2019 the work of Team MachineGenes was among that showcased in the United Nations' "AI for Good" Global Summit in Geneva, Switzerland.

Professor Jenny Gunton
Co-Founder/Chief Medical Officer

Professor Jenny Gunton is the main medical collaborator in Neuromathix's current development of prototype Artificial Pancreas software.

She holds a Chair in Medicine at Westmead Hospital, Sydney. Previously she has been a Senior Research Officer and Group leader, Diabetes and Transcription Factors, at the Garvan Institute of Medical Research, where she was a JDRF/NHMRC Fellow. She is a former President of the Australian Diabetes Society.

Her qualifications also include a post-doctoral Fellowship at the Joslin Diabetes Center and Harvard Medical School; a PhD from the University of Sydney; FRACP (Fellow of the Royal Australasian College of Physicians, subspecialty endocrinology and diabetes); and a MBBS (Bachelor of Medicine, Bachelor of Surgery).

Jenny is also a director-elect of Diabetes Neuromathix Pty Ltd.

Sir Michael Craig-Cooper CBE TD DL

Special Adviser (formerly Director and Chairman of the Audit and Risk Committee), National Bank of Kuwait (International) Plc. Solicitor (articled to the then President of the Law Society of England and Wales), subsequently with Allen and Overy, International Nickel Company of Canada Ltd, Carre Orban and Partners, and Chairman, Disciplinary Appeal Committee of Chartered Institute of Management Accountants.

Member, Court of the Drapers Company (Master 1997/98), and active with many other pro bono bodies including The Royal Hospital Chelsea (Chelsea Pensioners). Trustee of various bodies including The Thames Diamond Jubilee Foundation, The Mansion House Scholarship Scheme and The Lord Mayor’s Fund for Charities. Member, Council of the Imperial Society of Knights Bachelor.

Co-author with Lord Sheppard and Bain & Co Partners of books on management including ‘Management Audit – the management of change’ and with Lord Lane of Horsell and Professor N.Graham Maw ‘On Corporate Governance’.

Anders Engel Christensen

A Danish citizen and resident of Monaco, Anders holds a Master of Science in finance and economics, Aarhus University, Denmark (1986) and completed the executive program in strategy and organisation at the Stanford Business School, Stanford University (2000).

Since 2019, Anders has served as special advisor to the family office IPS (Monaco)/Canadian Overseas Packaging Group (Canada) and has been an active investor in a few selected start-up companies within the IT sector (e-commerce, artificial intelligence etc.) and/or driven by clean and sustainable economies, such as World Climate Foundation Ltd.(Denmark/UK), Sandcroft Avenue Ltd. trading as Hussle (UK), E-HubNordic ApS (Denmark) and the MachineGenes Group of companies (Australia, of which DNx is a member).

From 2010 to 2019 Anders served as CEO of the family office IPS/Canadian Overseas Packaging Group, with focus on the manufacturing of paper-based packaging solutions in East Africa, the Caribbean and the United Kingdom, and in international financial investments.

From 1986 to 2010 he worked in investment banking, primarily in Northern Europe (Nordea and ABN-Amro Alfred Berg, and then as partner and co-founder of Atrium Partners) providing financial advisory services in relation to capital market transactions (e.g. listing on a public stock exchange) and international mergers & acquisitions.

Dr Michael Burnet

Dr Burnet is founder and managing director of Synovo GmbH.

He is a graduate of the University of Melbourne and the University of Adelaide (PhD Biochemistry 1992). He completed postdoctoral research at the University of Montreal, University of Florida and the Institute National de la Recherche Agronomique a Versailles. In 1998 he became a project manager at Zeneca (formerly ICI) in the UK. In 2001 he became the Chief Scientific officer of Sympore GmbH based in Germany, and in 2004, he founded Synovo, a preclinical services and drug discovery company based in Tübingen, Germany. In 2005 he founded Hi-Cap formulations Ltd to develop intellectual property in the field of controlled release formulations. Both companies are profitable and have licensed intellectual property to multi-national enterprises. Michael is currently spinning out an oncology-focused company developing immune modulators.

Janelle Mason MBA

Janelle Mason is a financial services executive with experience gained in the United Kingdom and Australia across a wide range of areas including relationship management, credit risk, product development, strategy and project management. She is Executive Director – Institutional and Corporate at ANZ. Janelle has held directorships across a number of boards and advisory positions in various industries. She holds a Masters Business Administration from the University of Hull in the United Kingdom and a Bachelor of Business from Queensland University of Technology.